Travere Therapeutics (TVTX) Net Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 33.37% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -29.82% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 32.17% |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | -29.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.66% |
| Dec 31, 2025 | 46.20% |
| Sep 30, 2025 | 34.94% |
| Jun 30, 2025 | 29.08% |
| Mar 31, 2025 | -68.70% |
| Dec 31, 2024 | 39.82% |
| Sep 30, 2024 | -62.04% |
| Jun 30, 2024 | 44.77% |
| Mar 31, 2024 | -30.62% |
| Dec 31, 2023 | -36.15% |
| Sep 30, 2023 | 37.11% |
| Jun 30, 2023 | -34.34% |
| Mar 31, 2023 | 160.06% |
| Dec 31, 2022 | -241.56% |
| Sep 30, 2022 | -95.60% |
| Jun 30, 2022 | -146.35% |
| Mar 31, 2022 | 68.44% |
| Dec 31, 2021 | 7.05% |
| Sep 30, 2021 | 0.75% |
| Jun 30, 2021 | -62.65% |
| Mar 31, 2021 | 54.11% |
| Dec 31, 2020 | -558.10% |
| Sep 30, 2020 | -79.01% |
| Jun 30, 2020 | 53.18% |
| Mar 31, 2020 | 74.91% |
| Dec 31, 2019 | -29.39% |
| Sep 30, 2019 | -81.46% |
| Jun 30, 2019 | 66.46% |
| Mar 31, 2019 | -32.32% |
| Dec 31, 2018 | 20.40% |
| Sep 30, 2018 | 72.11% |
| Jun 30, 2018 | 55.07% |
| Mar 31, 2018 | -33.43% |
| Dec 31, 2017 | 27.09% |
| Sep 30, 2017 | 39.29% |
| Jun 30, 2017 | 9.37% |
| Mar 31, 2017 | 33.43% |
| Dec 31, 2016 | 62.42% |
| Mar 31, 2016 | -97.62% |